

AMENDMENTS

IN THE CLAIMS

Please replace claims 1, 2, 37, 49 and 63 with the following:

B¹

1. (Twice Amended) An expression cassette, comprising
a polynucleotide sequence encoding a polypeptide including an immunogenic HIV
Gag polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide
comprises a nucleotide sequence having at least 90% sequence identity to the sequence presented
as either nucleotides 844-903 of Figure 1 (SEQ ID NO:1) or nucleotides 841-900 of Figure 2
(SEQ ID NO:2).

2. (Twice Amended) An expression cassette, comprising
a polynucleotide sequence encoding a polypeptide including an immunogenic
HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide
comprises a nucleotide sequence having at least 90% sequence identity to the sequence presented
as Figure 1 (SEQ ID NO:3) or Figure 2 (SEQ ID NO:4).

B²

37. (Amended) The cell of claim 36, wherein the antigen presenting cell is a
lymphoid cell is selected from the group consisting of macrophage, monocytes, dendritic cells,
B-cells, T-cells, stem cells, and progenitor cells thereof.

B³

49. (Twice Amended) A method of generating an immune response in a subject,
comprising,

introducing the composition of claim 41 into said subject under conditions that are
compatible with expression of said expression cassette in said subject.

B⁴

63. (Twice Amended) The method of claim 62, where the method further comprises
administration of an HIV polypeptide.

Attached hereto is the **VERSION WITH MARKINGS TO SHOW CHANGES
MADE** and the **CURRENTLY PENDING CLAIMS**.

CURRENTLY PENDING CLAIMS

1. (Twice Amended) An expression cassette, comprising
a polynucleotide sequence encoding a polypeptide including an immunogenic HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide comprises a nucleotide sequence having at least 90% sequence identity to the sequence presented as either nucleotides 844-903 of Figure 1 (SEQ ID NO:1) or nucleotides 841-900 of Figure 2 (SEQ ID NO:2).
2. (Twice Amended) An expression cassette, comprising
a polynucleotide sequence encoding a polypeptide including an immunogenic HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide comprises a nucleotide sequence having at least 90% sequence identity to the sequence presented as Figure 1 (SEQ ID NO:3) or Figure 2 (SEQ ID NO:4).
3. The expression cassette of claim 2, wherein said polynucleotide sequence encoding a polypeptide including an HIV *Gag* polypeptide comprises a sequence having at least 90% sequence identity to the sequence presented as Figure 1 (SEQ ID NO:3).
4. The expression cassette of claim 2, wherein said polynucleotide sequence encoding a polypeptide including an HIV *Gag* polypeptide comprises a sequence having at least 90% sequence identity to the sequence presented as Figure 2 (SEQ ID NO:4).
5. The expression cassette of claim 2, wherein the polynucleotide sequence encoding said *Gag* polypeptide consists of a sequence having the sequence presented as Figure 1 (SEQ ID NO:3).
6. The expression cassette of claim 2, wherein the polynucleotide sequence encoding said *Gag* polypeptide consists of a sequence having the sequence presented as Figure 2 (SEQ ID NO:4).
7. The expression cassette of claim 2, wherein said polynucleotide sequence further includes a polynucleotide sequence encoding an HIV *protease* polypeptide.
8. The expression cassette of claim 2, wherein said polynucleotide sequence further includes a polynucleotide sequence encoding an HIV *polymerase* polypeptide.

CURRENTLY PENDING CLAIMS

9. (Amended) The expression cassette of any of claim 2, wherein said polynucleotide sequence further includes a polynucleotide sequence encoding an HIV *polymerase* polypeptide, wherein the sequence encoding the HIV *polymerase* polypeptide is modified by deletions of coding regions encoding reverse transcriptase and integrase.

10. (Amended) The expression cassette of claim 9, wherein said polynucleotide sequence encodes a polypeptide comprising T-helper cell and CTL epitopes.

11-23. Withdrawn.

24. (Amended) A recombinant expression system for use in a selected host cell, comprising, the expression cassette of claim 1, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected host cell.

25. The recombinant expression system of claim 24, wherein said control elements are selected from the group consisting of a transcription promoter, a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.

26. The recombinant expression system of claim 24, wherein said transcription promoter is selected from the group consisting of CMV, CMV+intron A, SV40, RSV, HIV-Ltr, MMLV-ltr, and metallothionein.

27. (Amended) A cell comprising the expression cassette of claim 1, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected cell.

28. The cell of claim 27, wherein the cell is a mammalian cell.

29. The cell of claim 28, wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.

30. The cell of claim 29, wherein said cell is a CHO cell.

31. The cell of claim 27, wherein the cell is an insect cell.

CURRENTLY PENDING CLAIMS

32. The cell of claim 31, wherein the cell is either *Trichoplusia ni* (Tn5) or Sf9 insect cells.
33. The cell of claim 27, wherein the cell is a bacterial cell.
34. The cell of claim 27, wherein the cell is a yeast cell.
35. The cell of claim 27, wherein the cell is a plant cell.
36. The cell of claim 27, wherein the cell is an antigen presenting cell.
37. (Amended) The cell of claim 36, wherein the antigen presenting cell is a lymphoid cell is selected from the group consisting of macrophage, monocytes, dendritic cells, B-cells, T-cells, stem cells, and progenitor cells thereof.
38. The cell of claim 27, wherein the cell is a primary cell.
39. The cell of claim 27, wherein the cell is an immortalized cell.
40. The cell of claim 27, wherein the cell is a tumor-derived cell.
41. (Amended) A composition for generating an immunological response, comprising:
the expression cassette of claim 1.
42. The composition of claim 41, further comprising a *Gag* polypeptide.
43. The composition of claim 41, further comprising an adjuvant.
- 44- 48. Withdrawn.
49. (Amended) A method of generating an immune response in a subject, comprising,
introducing the composition of claim 41 into said subject under conditions that are compatible with expression of said expression cassette in said subject.
50. The method of claim 49, wherein said expression cassette is introduced using a gene delivery vector.
51. The method of claim 50, wherein the gene delivery vector is a non-viral vector.

CURRENTLY PENDING CLAIMS

52. The method of claim 50, wherein said gene delivery vector is a viral vector.
53. The method of claim 52, wherein said gene delivery vector is a Sindbis-virus derived vector.
54. The method of claim 52, wherein said gene delivery vector is a retroviral vector.
55. The method of claim 52, wherein said gene delivery vector is a lentiviral vector.
56. The method of claim 49, wherein said composition delivered using a particulate carrier.
57. The method of claim 49, wherein said composition is coated on a gold or tungsten particle and said coated particle is delivered to said subject using a gene gun.
58. The method of claim 49, wherein said composition is encapsulated in a liposome preparation.
59. The method of any of claims 49-58, wherein said subject is a mammal.
60. The method of claim 59, wherein said mammal is a human.
61. Withdrawn.
62. (Amended) A method of generating an immune response in a subject, comprising introducing into cells of said subject the expression cassette of claim 1, under conditions that permit the expression of said polynucleotide and production of said polypeptide, thereby eliciting an immunological response to said polypeptide.
63. (Twice Amended) The method of claim 62, where the method further comprises administration of an HIV polypeptide.
64. The method of claim 63, wherein administration of the polypeptide to the subject is carried out before introducing said expression cassette.
65. The method of claim 63, wherein administration of the polypeptide to the subject is carried out concurrently with introducing said expression cassette.
66. The method of claim 63, wherein administration of the polypeptide to the subject is carried out after introducing said expression cassette.

CURRENTLY PENDING CLAIMS

67. An expression cassette comprising a polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2.
68. An expression cassette comprising a polynucleotide sequence of SEQ ID NO:3.
69. An expression cassette comprising a polynucleotide sequence of SEQ ID NO:4.
70. The expression cassette of claim 68, further comprising a nucleotide sequence encoding an HIV protease polypeptide.
71. The expression cassette of claim 69, further comprising a nucleotide sequence encoding an HIV protease polypeptide.
72. The expression cassette of claim 68, further comprising a nucleotide sequence encoding an HIV polymerase polypeptide.
73. The expression cassette of claim 69, further comprising a nucleotide sequence encoding an HIV polymerase polypeptide.
74. A composition for generating an immunological response in a mammal comprising the expression cassette of claim 67.
75. A method of generating an immune response in a mammal, the method comprising the step of intramuscularly administering the expression cassette of claim 67 to said mammal.